AqueSys

Aliso Viejo, United States Founded: 2006 • Age: 20 yrs Acquired By Allergan
Implantable devices for glaucoma treatment are developed by AqueSys.

About AqueSys

AqueSys is a Healthcare company based in Aliso Viejo (United States) founded in 2006, and was acquired by Allergan in September 2015. Implantable devices for glaucoma treatment are developed by AqueSys. AqueSys has raised $87.6 million across 4 funding rounds from investors including The Carlyle Group, Allergan and Accuitive Medical Ventures. Its focus areas include Life Sciences, Ophthalmology, Medical Devices and Therapy. Its competitors include Glaukos, Ivantis and Myra Vision; 3 of its 3 listed competitors have raised funding.

Company details

AqueSys was founded in 2006 in Aliso Viejo, United States, as an ophthalmic company. Focus is placed on implantable devices to manage glaucoma. The XEN Gel Stent, a gelatin-based implant for intraocular pressure control, was developed and received CE Mark approval in Europe. Injection occurs via a preloaded device through a self-sealing incision. Acquisition by Allergan took place in 2015, with US approval pending at that time.

  • Headquarters Aliso Viejo, United States
  • Stage Acquired
  • Sectors
    Healthcare
  • Website aquesys.com
  • Social LinkedIn
  • Acquired by Allergan (Sep 2015)
Operational Areas
Key Metrics
  • Total Equity Funding
    $87.6M (USD)

    in 4 rounds

  • Latest Funding Round
    $43.6M (USD), Series D

    Jan 2014

  • Investors
  • Acquired by
    Allergan

    (Sep 2015)

Funding Insights of AqueSys

AqueSys has successfully raised a total of $87.6M across 4 strategic funding rounds. The most recent funding activity was a Series D round of $43.6 million completed in January 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $87.6M
  • Total Rounds 4
  • Last Round Series D β€” $43.6M
  • First Round $9M

    (Jul 2008)

  • Investors Count 5

All 4 funding rounds of AqueSys with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jan 2014$43.6MSeries D––
May 2012$12MDebt – Conventional––
–
Jun 2010$35MSeries C–Longitude Capital, Rho Capital Partners
Jul 2008$9MSeries B––
Valuation history

6 investors in total: 6 institutional.

Investors in AqueSys

AqueSys has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include The Carlyle Group, Allergan and Accuitive Medical Ventures.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Early-stage US healthcare investments are made by Accuitive Medical Ventures.
amvpartners.comDuluth, United States
Private equity firm focused on life science sector
longitudecapital.comMenlo Park, United States
Private equity investments are directed toward multiple sectors.
1986carlyle.com
Venture capital fund focused on early-stage healthcare startups
svhealthinvestors.comBoston, United States
Early-stage tech startups are invested in by Rho Capital Partners.
rho.comNew York, United States
A portfolio of generic medicines is developed and manufactured.
1948allergan.comMadison, United States
Premium access

Investor details for AqueSys

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Timeline of AqueSys

4 dated milestones of AqueSys across 9 years, from founding to its latest funding, stage changes and deals.

  1. Founded AqueSys is founded.
  2. Funding First funding round of $9.0M.
  3. Funding Latest funding round, Series D, of $43.6M.
  4. Exit Acquired by Allergan.

Competitors of AqueSys

AqueSys has 3 listed competitors in our database, 3 of them funded. They include Glaukos, Ivantis and Myra Vision.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
glaukos.com2001Laguna Hills, United States$117.57M907
Developer of implants to treat glaucoma
ivantisinc.com2007Irvine, United States$166.23M132
Implantable device to relieve intraocular pressure in open angle glaucoma
myravision.com2019Campbell, United States$42M
Nanotechnology-based devices for glaucoma treatment are developed.
Premium access

Detailed competitors of AqueSys

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Ophthalmology

3 companies that operate in the same segment as AqueSys (Ophthalmology) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Developer of a wide range of eye care products
1945Fort Worth, Texas, United StatesUSD 171.61 MUSD 24.69 B25,941
Genetic medicines are developed by 4DMT for transformative therapies.
2013Emeryville, California, United StatesUSD 186.59 MUSD 85.21 M227
Developer of antibodies to treat complement-mediated neurodegenerative diseases
2011San Francisco, California, United StatesUSD 256 M100
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Aquesys

AqueSys, Inc. Closes $35M Series C Round
PR Newswire β€’ 16 years ago
AqueSys Adds $9 Million - PE Hub
Pehub β€’ 18 years ago
Premium access

Complete news archive for AqueSys

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about AqueSys

AqueSys was founded in 2006 and raised its 1st funding round 2 years after it was founded.

AqueSys is headquartered in Aliso Viejo, United States. It is registered at Aliso Viejo, California, United States.

AqueSys is a funded company, having raised a total of $87.6M across 4 funding rounds to date. The company's 1st funding round was a Series B of $9M, raised on Jul 2008.

AqueSys was founded in 2006 in Aliso Viejo, United States, as an ophthalmic company. Focus is placed on implantable devices to manage glaucoma. The XEN Gel Stent, a gelatin-based implant for intraocular pressure control, was developed and received CE Mark approval in Europe. Injection occurs via a preloaded device through a self-sealing incision. Acquisition by Allergan took place in 2015, with US approval pending at that time.

AqueSys's top competitors include Glaukos, Myra Vision and Ivantis.

AqueSys has 6 investors. Key investors include The Carlyle Group, Allergan, Accuitive Medical Ventures, Longitude Capital, and SV Health Investors.

Yes. AqueSys was acquired by Allergan in September 2015.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available